BeiGene’s (ONC) sonrotoclax was granted FDA orphan designation as a treatment of myelodysplastic syndromes, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene price target raised to $313 from $259 at Macquarie
- BeiGene price target raised to $348 from $345 at Guggenheim
- BeiGene price target raised to $348 from $288 at Citizens JMP
- BeiGene’s Strong Financial Performance and Strategic Positioning Earns Buy Rating
- BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings
Questions or Comments about the article? Write to editor@tipranks.com